Status:
COMPLETED
Hypofractionated 3-Dimensional Radiation Therapy in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer. ICORG 99-09
Lead Sponsor:
Cancer Trials Ireland
Conditions:
Lung Cancer
Eligibility:
All Genders
Up to 120 years
Phase:
PHASE2
Brief Summary
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor over a shorter period of time may kill more tumor cells and cause less damage to normal tissue. P...
Detailed Description
OBJECTIVES: Primary * To evaluate the acute and long-term radio-induced toxicity (any organ) of hypofractionated 3-dimensional conformal radiotherapy in patients with newly diagnosed stage I-III non...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed newly diagnosed non-small cell lung cancer meeting 1 of the following stage criteria:
- Stage I or II disease
- Medically inoperable or patient refused surgery
- Stage IIIA or IIIB disease (no pleural effusions)
- Radiation dose parameters must satisfy the required study dose-volume constraints
- PATIENT CHARACTERISTICS:
- Karnofsky performance status 70-100%
- Weight loss ≤ 10% within 3 months before diagnosis
- No other malignancy within the past 5 years, except nonmelanoma skin cancer
- No clinically significant cardiovascular disease (e.g., hypertension \[blood pressure \> 150/100 mm Hg\], myocardial infarction or stroke within the past 6 months, or unstable angina)
- PRIOR CONCURRENT THERAPY:
- No concurrent chemotherapy
Exclusion
Key Trial Info
Start Date :
November 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00955175
Start Date
November 1 2000
Last Update
February 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Luke's Hospital
Dublin, Ireland, 6